Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. (AVTX) reported insider transactions by Chief Medical Officer Mittie Doyle. On August 17, 2026, Doyle exercised options to acquire 1,000 shares of common stock at $12.65 per share and sold 1,000 shares at $20.00 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle directly owned 123,750 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,000 shares ($7K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Doyle Mittie
Role
Chief Medical Officer
Sold
1,000 shs ($20K)
Approx. gross sale proceeds
$20K
Approx. exercise cost
$13K
Approx. pre-tax spread
$7K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F2 | 1,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,000 | $12.65 | $13K |
| Sale | Common Stock F1 | 1,000 | $20.00 | $20K |
Holdings After Transaction:
Stock Option (Right to Buy) — 123,750 shares (Direct);
Common Stock — 51,776 shares (Direct)
Footnotes (2)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options Exercised: 1,000 shares
Option Exercise Price: $12.65 per share
Shares Sold: 1,000 shares
+4 more
7 metrics
Options Exercised
1,000 shares
Stock Option (Right to Buy) exercised on August 17, 2026
Option Exercise Price
$12.65 per share
Exercise price for 1,000-stock-option derivative security
Shares Sold
1,000 shares
Common Stock sale on August 17, 2026
Sale Price
$20.00 per share
Per-share price for 1,000 common shares sold
Post-transaction Holdings
123,750 shares
Directly owned common shares after option exercise
Option Expiration Date
July 15, 2034
Expiration date of the exercised stock option
10b5-1 Plan Adoption Date
November 13, 2025
Date Mittie Doyle adopted Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security, Common Stock
4 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported ... were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transaction did AVTX Chief Medical Officer Mittie Doyle report on this Form 4?
Mittie Doyle reported exercising 1,000 stock options at $12.65 and selling 1,000 common shares at $20.00 on August 17, 2026. The option exercise and share sale were reported as separate transactions on the same date.
Was Mittie Doyle’s AVTX trading done under a Rule 10b5-1 plan?
Yes. The Form 4 states that all reported transactions were effected under a Rule 10b5-1 trading plan adopted by Mittie Doyle on November 13, 2025, indicating the trades were pre-arranged under that plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
